Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Inclusion Criteria

• •All Participants
• •Able to provide 1) written, informed consent or 2) assent if a care partner can provide consent.
• •Access to a primary care or neurology provider for ongoing care.
• •1\) willing to undergo skin biopsy or lumbar puncture for alpha-synuclein testing or 2) has access to as-yet undisclosed skin biopsy or lumbar puncture alpha-synuclein testing results.
• •Healthy/Asymptomatic Arm
• •Undergoing testing for defined reason (e.g., research study)
• •Mini-Mental State Examination score between 26 and 30 (or MoCA between 25 and 30)
• •General good health (no diseases expected to interfere with the study)
• •Symptomatic Arm \[Concern for dementia with Lewy bodies (DLB), Parkinson's disease (PD), or multiple system atrophy (MSA)\]
• •Referred by a neurologist or movement disorder specialist
• •Adults with any of the following: symptomatic LBD, mild cognitive impairment with Lewy body (MCI-LB), Parkinson's disease dementia (PDD), MCI in Parkinson's disease (PD-MCI), or criteria for multiple system atrophy (MSA).